OBR Oncology’s Thursday daily newsfeed included an article from The American Journal of Managed Care®
). The article, “Azar Announces Mandatory Oncology Payment Model is Coming
,” covered the HHS secretary’s announcement that the administration will revisit mandatory models that it had previously scrapped in cardiac care and that the time had come for “exploring new and improved episode-based models in other areas, including radiation oncology.”
’s The Center for Biosimilars®
’ article “FDA Approves Coherus’ Pegfilgrastim Biosimilar, Udenyca
” was highlighted in OBR Oncology's Monday daily newsfeed. The article reported that, after previous US regulatory setbacks, the manufacturer had gained approval for its biosimilar, referencing Neulasta, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia.